Selective PI3Kα Inhibitors for Tumor Inhibition With Lower Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing PI3K inhibitors face challenges in achieving sufficient target inhibition in tumors while avoiding toxicity in cancer patients due to their non-selective isoform inhibition, leading to side effects such as diarrhea, rash, fatigue, and hyperglycemia.
Innovation Solution
Development of selective PI3Kα inhibitors, represented by compounds of formula I, which are designed to target PI3Kα specifically, thereby increasing the therapeutic window and reducing off-target toxicities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pan-PI3K inhibitors are used to achieve target inhibition in tumors, then tumor inhibition is improved, but toxicity increases due to non-selective isoform inhibition
Solution Approach 1:
The patent segments the PI3K inhibitor activity into isoform-specific inhibition, where the compound selectively inhibits PI3Kα while sparing other isoforms (PI3Kβ, PI3Kδ, PI3Kγ). This segmentation allows tumor inhibition through PI3Kα suppression while avoiding toxicities associated with pan-isoform inhibition, directly resolving the contradiction between efficacy and safety
Solution Approach 2:
The compound exhibits local quality in its inhibitory activity by demonstrating preferential binding to the PI3Kα isoform through specific structural interactions with the p110α catalytic subunit. This localized selectivity enables the drug to exert its anti-tumor effect specifically through PI3Kα inhibition while maintaining normal function of other PI3K isoforms, thereby achieving tumor inhibition without pan-isoform toxicity
2Reliability
If pan-PI3K inhibitors are used to achieve sufficient target inhibition, then therapeutic effect is improved, but side effects increase
Solution Approach 1:
The inhibitor segments its therapeutic action by selectively targeting only the PI3Kα isoform, which is the primary driver of tumorigenesis in many cancers. This segmentation concentrates the therapeutic effect on the relevant isoform while excluding other isoforms from inhibition, thereby achieving sufficient target inhibition for therapeutic benefit while minimizing side effects such as diarrhea, rash, fatigue, and hyperglycemia that result from non-selective isoform suppression
Solution Approach 2:
The patent achieves isoform-selective inhibition by modifying molecular parameters of the inhibitor compound, including its chemical structure and binding affinity characteristics. These parameter changes enable the compound to differentiate between PI3K isoforms based on subtle structural differences in their catalytic domains, allowing selective PI3Kα inhibition that provides therapeutic effect while avoiding the side effects associated with broader isoform suppression
Data Source
AI summary
The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of PI3Kα enzymes with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with PI3Kα signaling with the compounds and compositions of the disclosure.